Online citations, reference lists, and bibliographies.
← Back to Search

CNS Metastases In Breast Cancer Patients: Prognostic Implications Of Tumor Subtype

C. Bachmann, S. Schmidt, A. Staebler, T. Fehm, F. Fend, J. Schittenhelm, D. Wallwiener, E. Grischke
Published 2014 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Abstract Development of brain metastases (BM) in breast cancer leads to limited survival. The therapeutical options are limited. There are less data about the risk factors and prognostic importance in BM. Objective is to investigate predictors of central nervous system metastases and outcome after diagnosis of BM according to tumor subtype. Based on medical records, 80 consecutive patients with primary non-metastatic operable breast cancer, treated at Department of Gynecology, University of Tübingen, and who developed BM during follow-up, were retrospectively analyzed. Clinicopathological parameters and their prognostic impact were evaluated. A node involvement (40 %), ER/PR negative (53.75 vs. 61.25 %), triple negative (28.75 %) and HER2+ status (40 %) were associated with BM. BM in breast cancer patients lead to a shortened survival. In cerebral metastatic breast cancer patients with HER2-negative and triple-negative, patients had significant shorter survival after detection of BM compared with HER2-positive and non-triple-negative patients (p = 0.001; p = 0.03). Risk of BM varies significantly by subtype. Understanding the biology of metastases can help categorize patients into prognostically useful categories and tailor treatment regimens for individual patients. Prospective clinical trials would be required for evaluating the potential role of screening for asymptomatic BM and of treatment of triple-negative patients.
This paper references
10.1093/annonc/mdn682
Survival among women with triple receptor-negative breast cancer and brain metastases.
S. Dawood (2009)
Do we need HER - 2 / neu testing for all patients with primary breast carcinoma ?
CK Anders (2003)
10.1007/s11060-007-9420-5
Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer
R. Bartsch (2007)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1016/J.YONC.2010.12.003
Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Central Nervous System Metastases
J. Thigpen (2011)
10.1093/ANNONC/MDL064
Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG).
B. Pestalozzi (2006)
10.1007/s00432-013-1511-4
Receptor change-clinicopathologic analysis of matched pairs of primary and cerebral metastatic breast cancer
C. Bachmann (2013)
Do we need HER-2/neu testing for all patients with primary breast carcinoma? Cancer
S Taucher (2003)
10.1038/modpathol.3800830
Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer
J. Gaedcke (2007)
10.1016/j.ctrv.2013.01.006
A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer.
P. B. Larsen (2013)
10.1200/JCO.2002.04.016
HER2 in brain metastases: issues of concordance, survival, and treatment.
I. Fuchs (2002)
subtype , age , and race among patients with breast cancer brain metastases
F Heitz (2011)
10.1016/S1470-2045(13)70335-8
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
D. Cameron (2013)
10.1056/NEJMOA052122
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
E. H. Romond (2005)
10.1200/JCO.2008.19.9844
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review.
S. Dawood (2010)
10.1002/cncr.25746
The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases
C. Anders (2011)
Multifactorial Central Nervous System Recurrence Susceptibility in Patients With HER 2-Positive Breast Cancer Epidemiological and Clinical Data From a Population-Based Cancer Registry Study
Antonino Musolino (2011)
10.1186/bcr2603
HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer
L. D. Da Silva (2010)
10.1200/JCO.2005.04.173
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
M. Marty (2005)
10.1007/s00432-012-1358-0
CNS metastases of breast cancer show discordant immunohistochemical phenotype compared to primary
C. Bachmann (2012)
10.1016/j.critrevonc.2009.04.011
The upgraded role of HER3 and HER4 receptors in breast cancer.
A. Koutras (2010)
10.1200/JCO.2006.07.0250
Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer.
Z. Gabos (2006)
10.1186/bcr2699
Breast histoscanning: the development of a novel technique to improve tissue characterization during breast ultrasound
L. Wilkinson (2010)
10.1016/J.YONC.2012.08.029
Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors
J. Thigpen (2012)
10.5858/arpa.2012-0541-OA
Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
A. Wiens (2014)
10.1043/1543-2165(2007)131[18:ASOCCO]2.0.CO;2
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
A. Wolff (2007)
the M77001 study group
M Marty (2015)
10.1002/cncr.11828
Do we need HER‐2/neu testing for all patients with primary breast carcinoma?
S. Taucher (2003)
10.1002/IJC.2910490504
Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer
O. Kallioniemi (1991)
10.1093/annonc/mdr022
Breast carcinoma with brain metastases: clinical analysis and immunoprofile on tissue microarrays.
E. Brogi (2011)
10.1093/annonc/mdq625
Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival.
F. Heitz (2011)
10.1002/cncr.25771
Multifactorial central nervous system recurrence susceptibility in patients with HER2‐positive breast cancer
A. Musolino (2011)



This paper is referenced by
10.18632/oncotarget.27453
Risk factors for breast cancer brain metastases: a systematic review
Lola Koniali (2020)
10.1016/j.breast.2020.02.007
Clinical outcome of patients with brain metastases from breast cancer - A population based study over 21 years
A. Thulin (2020)
10.1038/s41698-018-0047-0
Organotropism: new insights into molecular mechanisms of breast cancer metastasis
Wenjing Chen (2018)
10.1007/s10585-020-10055-x
Nintedanib and a bi-specific anti-VEGF/Ang2 nanobody selectively prevent brain metastases of lung adenocarcinoma cells
B. Kovalchuk (2020)
10.1007/s11060-018-2805-9
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer
A. Darlix (2018)
10.1007/978-3-030-42958-4_1
Epidemiology and Socioeconomic Impact of CNS Metastases
Jessica A Wilcox (2020)
10.1007/978-3-319-57901-6_23
Neurological Complications of Breast Cancer and Its Treatment
E. L. Rhun (2018)
Treatment Of Breast Cancer; Review And Updates.
Muhammad Furrukh (2018)
10.1016/j.clbc.2017.08.004
Predicting Brain Metastasis in Breast Cancer Patients: Stage Versus Biology
H. Azim (2018)
10.3389/fimmu.2019.02294
Microenvironmental Heterogeneity in Brain Malignancies
Lucas J. M. Perus (2019)
10.3892/ol.2017.7637
Estrogen receptor-α promoter methylation is a biomarker for outcome prediction of cisplatin resistance in triple-negative breast cancer
Junnan Xu (2018)
10.1186/s13058-018-1093-9
Using an in-vivo syngeneic spontaneous metastasis model identifies ID2 as a promoter of breast cancer colonisation in the brain
M. Kijewska (2018)
10.1016/j.trecan.2018.01.003
The Evolving Landscape of Brain Metastasis.
M. Valiente (2018)
Semantic Scholar Logo Some data provided by SemanticScholar